Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Trial of Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy in Patients With Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

NCT07879469 is registered in ClinicalTrials.gov with Tianjin Medical University Second Hospital as lead sponsor.

NCT NCT07879469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07879469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Trial of Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy in Patients With Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
Lead sponsor
Tianjin Medical University Second Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 20, 2026
Completion date
October 1, 2029
Enrollment
150 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

antibody-drug conjugates, bladder (urothelial, transitional cell) cancer, chemotherapy, immunotherapy, systemic therapy